About NeoGenomics, Inc.
https://www.neogenomics.comNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
CEO
Anthony P. Zook
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2003-04-16 | Reverse | 1:100 |
| 2000-11-17 | Forward | 4:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 156
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
TD Cowen
Buy
Needham
Buy
Goldman Sachs
Buy
Stephens & Co.
Overweight
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:19.67M
Value:$260.04M
BLACKROCK, INC.
Shares:19.3M
Value:$255.13M
VANGUARD GROUP INC
Shares:13.9M
Value:$183.81M
Summary
Showing Top 3 of 343
About NeoGenomics, Inc.
https://www.neogenomics.comNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $187.8M ▲ | $107.46M ▼ | $-27.13M ▲ | -14.45% ▲ | $-1.05 ▲ | $-9.95M ▲ |
| Q2-2025 | $181.33M ▲ | $124.89M ▲ | $-45.09M ▼ | -24.87% ▼ | $-1.75 ▼ | $-27.62M ▼ |
| Q1-2025 | $168.03M ▼ | $101.07M ▲ | $-25.92M ▼ | -15.43% ▼ | $-1 ▼ | $-6.31M ▼ |
| Q4-2024 | $172M ▲ | $95.66M ▼ | $-15.32M ▲ | -8.91% ▲ | $-0.6 ▲ | $3.68M ▲ |
| Q3-2024 | $167.82M | $96.08M | $-17.7M | -10.55% | $-0.7 | $1.78M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $164.12M ▲ | $1.37B ▼ | $536.49M ▼ | $838.29M ▼ |
| Q2-2025 | $163.69M ▼ | $1.39B ▼ | $539.91M ▼ | $854.04M ▼ |
| Q1-2025 | $358.08M ▼ | $1.6B ▼ | $713.16M ▼ | $888.27M ▼ |
| Q4-2024 | $386.84M ▼ | $1.64B ▼ | $735.7M ▲ | $902.34M ▼ |
| Q3-2024 | $387.81M | $1.64B | $732.9M | $908.21M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-27.13M ▲ | $8.88M ▼ | $-277K ▲ | $765K ▲ | $9.39M ▲ | $570K ▼ |
| Q2-2025 | $-45.09M ▼ | $20.33M ▲ | $-9.31M ▼ | $-202.43M ▼ | $-191.47M ▼ | $14.01M ▲ |
| Q1-2025 | $-25.92M ▼ | $-25.33M ▼ | $3.56M ▲ | $949K ▲ | $-20.82M ▼ | $-29.83M ▼ |
| Q4-2024 | $-15.32M ▲ | $9.8M ▲ | $-5.47M ▼ | $687K ▼ | $5.02M ▼ | $-1.8M ▼ |
| Q3-2024 | $-17.7M | $9.25M | $-3.52M | $1.18M | $6.91M | $-1.55M |
Revenue by Products
| Product | Q3-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Commercial Insurance | $0 ▲ | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 Clinical Services | $150.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Anthony P. Zook
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2003-04-16 | Reverse | 1:100 |
| 2000-11-17 | Forward | 4:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 156
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
TD Cowen
Buy
Needham
Buy
Goldman Sachs
Buy
Stephens & Co.
Overweight
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:19.67M
Value:$260.04M
BLACKROCK, INC.
Shares:19.3M
Value:$255.13M
VANGUARD GROUP INC
Shares:13.9M
Value:$183.81M
Summary
Showing Top 3 of 343